Advertisement

Genzyme Corp., the subsidiary of French drug company Sanofi SA, will be restructured to trim down Cambridge biotech’s units, a Genzyme official confirmed.

Genzyme employees received a Sanofi employee bulletin indicating that the Cambridge company will continue to operate as a unit of Sanofi, but that it will be a smaller unit made up only of Genzyme’s personalized genetic health and multiple sclerosis businesses. Sanofi plans to roll Genzyme’s other businesses – including oncology, biosurgery and renal operations – into its own businesses. No layoffs have been announced.

SOURCE

Advertisement
Advertisement